Genprex Inc. announced the enrollment of the first patient in the Phase 2 expansion of its Acclaim-3 clinical trial for Reqorsa Gene Therapy in small cell lung cancer, aiming to enroll 50 patients across 10 to 15 U.S. sites, with a primary endpoint of 18-week progression-free survival.